Psychobiotics Explained: Strain-Level Evidence, Not Brand Claims

What psychobiotics actually are

"Psychobiotic" was defined in 2013 by Dinan, Stanton and Cryan as a live organism that, taken in adequate amounts, benefits people with psychiatric illness. In practice the word now gets applied to almost any probiotic marketed for mood, stress or focus. It is not a regulatory category and it guarantees nothing: plenty of products carry it with no strain-level human evidence at all. This reference works the other way round, strain by strain, so you can check a label against an actual trial rather than a marketing claim.

Going strain by strain matters because results do not transfer automatically between strains of the same species. A trial of one Lactobacillus rhamnosus strain tells you nothing certain about another, so a label that says only "contains L. rhamnosus" is telling you very little about whether it resembles anything studied.

Why strain identity is the whole game

Probiotic research specifies a strain code — JB-1, 1714, PS128, NCC3001 — alongside the genus and species. If a label omits the strain code, there is no way to connect it to a specific trial. The gut-brain axis existing does not mean any given capsule engages it usefully.

Strain-by-strain evidence summary

• Lactobacillus rhamnosus JB-1 — in mice, it reduced stress-induced corticosterone and anxiety- and depression-related behaviour, and the effects disappeared when the vagus nerve was cut (Bravo et al., 2011). In people, an eight-week randomised, placebo-controlled crossover trial in 29 healthy men (Kelly et al., 2017) found no effect on mood, anxiety, stress, sleep quality, the cortisol stress response or cognitive performance. Strong animal data, null human data.
• Bifidobacterium longum 1714 — 22 healthy men took a placebo for four weeks and then the strain (1 billion colony-forming units a day) for four weeks, in that fixed order (Allen et al., 2016). The cortisol and anxiety response to a stress test was smaller, daily reported stress fell and there were subtle improvements on a visuospatial memory task. The design was not randomised, the sample was small, and the strain's supplier provided the product and employed one author.
• Lactobacillus plantarum PS128 — small trials by Taiwanese groups. In 40 adults with self-reported insomnia, 30 days of PS128 lowered depression questionnaire scores and fatigue compared with placebo (Ho et al., 2021). A four-week trial in boys with autism reported improvement in some behaviour measures (Liu et al., 2019). An eight-week trial in 116 high-stress workers, mostly firefighters, used PS128 combined with a heat-treated second strain and reported lower job stress, state anxiety and insomnia scores than placebo, with no change in cortisol (2025). An author of the first two studies holds stock in Bened Biomedical, which funded the third.
• Bifidobacterium longum NCC3001 — in 44 adults with irritable bowel syndrome and mild to moderate anxiety or depression (Pinto-Sanchez et al., 2017), 14 of 22 on the strain had a depression-score drop of at least two points after six weeks, against 7 of 22 on placebo. It had no significant effect on anxiety or on bowel symptoms, and the population limits how far the finding applies to healthy people.
• Lactobacillus helveticus R0052 + Bifidobacterium longum R0175 — in healthy volunteers, 30 days of this combination lowered psychological distress scores and urinary cortisol compared with placebo (Messaoudi et al., 2011). An eight-week trial of an L. helveticus and B. longum preparation in 79 people selected for low mood found no difference from placebo on any psychological outcome (Romijn et al., 2017).

Comparing the named strains

In a 2019 meta-analysis of 34 controlled trials of prebiotics and probiotics, probiotics had a small effect on depression scores and a very small one on anxiety (Liu et al., 2019). Psychobiotic trials are still small, short and often run by groups with a commercial interest in the strain — not disqualifying, but a reason to treat no single trial as settled.

How to read a label against this list

1. Find the exact strain code on the packaging — not just the genus and species.
2. Check whether that specific code appears in a published human trial, not only an animal study.
3. Compare the dose (in colony-forming units, CFU) with the dose used in the trial; many products under-dose relative to the research.
4. Note the trial population — healthy adults, IBS patients and children are not interchangeable.
5. Note the trial duration, typically four to eight weeks, and don't expect faster results than the trial measured.
6. Look for third-party testing or a certificate of analysis if you want assurance that the count on the label is what is in the capsule.

Some strains sold as gut-health products have research that is mainly metabolic or digestive rather than psychiatric. That is a good illustration that "psychobiotic" cannot be applied to a whole brand's range — it has to be assessed strain by strain, product by product.

Where the evidence genuinely stops

Nothing in the current strain-level literature supports psychobiotics as a treatment for diagnosed depression or anxiety disorders, as a substitute for sleep or exercise, or as a fast-acting cognitive enhancer. The honest position: a short list of specific strains have produced small effects on stress physiology or self-reported mood in small, mostly short trials, several of which have not replicated. If your interest is buying decisions rather than mechanism, seeprobiotics for mood and anxiety; for cognitive endpoints, seeprobiotics for brain health; and for food sources,probiotic foods for brain function.

Safety and tolerability

Probiotics have a long history of apparently safe use, particularly in healthy people, but according toNCCIH few studies have examined their safety in detail, and the risk of harmful effects is greater in people with severe illnesses or compromised immune systems. If that applies to you, or you are considering a probiotic for a premature infant or someone seriously ill, talk to a clinician first. If you take psychiatric medication, discuss any addition with your prescriber rather than using a probiotic in place of treatment.

The primary studies are searchable atPubMed, which is a better first stop than a brand's own citations page, since brands tend to cite only the favourable trials.

Key takeaways

• "Psychobiotic" is not a regulated category; only specific named strains have trial data, not species or genera in general.
• L. rhamnosus JB-1's evidence is in mice; its human trial was null.
• B. longum 1714, PS128, NCC3001 and the R0052 + R0175 combination have small positive human studies, each with real limitations.
• Match strain code, dose, population and trial length on any label before assuming it does what the marketing implies.
• None of these strains is a substitute for sleep, exercise or clinical mental-health treatment.

Common questions

Is "psychobiotic" an official term?

No. It was defined in the research literature in 2013, but there is no regulatory definition, so any company can apply it loosely.

Which single strain has the best human evidence right now?

None stands clearly ahead. B. longum NCC3001 and the R0052 + R0175 combination have randomised, placebo-controlled trials with positive results, but in narrow or small samples, and the combination's later trial in people with low mood was null. B. longum 1714's best-known study was not randomised.

Can I combine several psychobiotic strains for a stronger effect?

There is no evidence that stacking strains multiplies benefits. Some positive trials used two-strain combinations, but only that exact combination was tested — an arbitrary multi-strain blend inherits none of its results.

How does this differ from a general gut-brain approach?

This page is strain-specific. For the broader picture of how the gut and brain communicate, seethe gut-brain axis explained.